Evaluation of long-term pharmacist-led prospective audit and feedback in antimicrobial stewardship: An 8-year study

Am J Infect Control. 2024 Jun;52(6):670-677. doi: 10.1016/j.ajic.2023.12.013. Epub 2023 Dec 23.

Abstract

Background: Limited research has evaluated the long-term outcomes of prospective audit and feedback (PAF) led by pharmacists. We assessed pharmacist-led PAF processes and outcome measures over 8 years.

Methods: This study was conducted at a single public hospital in Japan. Between 2014 and 2021, pharmacists conducted weekday PAFs for hospitalized patients and annually evaluated the process and outcome measures. The endpoints included detection of drug-resistant bacteria, drug susceptibility rates, duration of antimicrobial therapy, and proportion of long-term administration.

Results: Among inpatients, methicillin-resistant Staphylococcus aureus significantly decreased from 50.9% in 2014 to 32.8% in 2021 (P < .001). The susceptibility rate of Pseudomonas aeruginosa to meropenem significantly increased from 91.2% in 2014 to 94.4% in 2021 (P < .001) and levofloxacin increased from 84.9% in 2014 to 89.3% in 2021 (P < .001). Antimicrobial therapy duration did not differ significantly between 2014 and 2016, but decreased significantly from 2017 onwards (P < .001), except in 2018. The number of patients receiving intravenous antimicrobials for >10 days decreased significantly between 2014 and 2021 (P < .001).

Conclusions: Long-term continuous PAF interventions by pharmacists contribute to improving and maintaining process and outcome indicators and prevent the spread of drug-resistant bacteria.

Keywords: Antimicrobial resistance; Intervention; Japan; Methicillin-resistant Staphylococcus aureus; Outcome; Pseudomonas aeruginosa.

Publication types

  • Research Support, Non-U.S. Gov't

MeSH terms

  • Anti-Bacterial Agents* / therapeutic use
  • Antimicrobial Stewardship* / methods
  • Feedback
  • Female
  • Humans
  • Japan
  • Male
  • Pharmacists*
  • Prospective Studies
  • Pseudomonas aeruginosa / drug effects

Substances

  • Anti-Bacterial Agents